Pilanz Use In Pregnancy & Lactation

Pregnancy: Pregnancy category C.
There are no adequate and well-controlled studies to date using Olanzapine in pregnant women, and the drug should be used during pregnancy only when the potential benefit justify the potential risk to the fetus. Women should be advised to notify their clinician if they become pregnant or plan to become pregnant during therapy with the drug. There is the report in infants born to mothers who had used Olanzapine during the third trimester of pregnancy are at risk for abnormal muscle movements (extrapyramidal symptoms) and/or withdrawal symptoms. Symptoms in the infant may include agitation, hypertonia, hypotonia, tardive dyskinetic-like symptoms, tremor, somnolence, respiratory distress and feeding disorder.
Lactation: Olanzapine is distributed into milk. The mean dosage received by an infant at steady state is estimated to be about 1.8% of the maternal dosage. Women should avoid breast-feed during receiving Olanzapine.